Clinical trial NCT02538432: Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
Official title: 15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Prostate Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Keywords: Disease Progression
Non-Responsive Disease
Advanced Disease
Lead sponsor: University of Maryland, Baltimore
Sponsor class: OTHER
First posted: 2015-09-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.

Detailed description: This is a phase II trial of (RQ-07) in advanced solid tumors in advanced prostate, breast or lung cancer. The purpose of this trial is to determine whether the administration of the study drug RQ-07 can decrease circulating tumor cells in advanced prostate, breast or lung cancer. Additionally, the study will evaluate whether the study drug may improve outcome in advanced prostate, breast or lungs cancer either by itself or when combined with gemcitabine, a standard chemotherapy drug. The combination of with gemcitabine will only be investigated after disease has worsened with the study drug RQ-07 by itself and only in patients with prostate or lung cancer.

Eligibility criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed breast, prostate or non-small cell lung cancer or other A tissue block, 10 unstained slides or fresh tissue biopsy is required.
2. At least 2 weeks should have elapsed since the last treatment and patients should have recovered from previous significant toxicity (i.e. to grade 1 or less).
3. ECOG Performance Status \<2.
4. Patient at least 18 years of age or older.
5. Adequate hematological function as defined by the protocol, section 4.1.5.
6. Patients must have a serum creatinine within normal limits, or an estimated or measured creatinine clearance \> 35 mg/ml/min.
7. Normal serum electrolytes (no \>grade 2 abnormalities), magnesium and phosphorus on the day of therapy. Correction of abnormalities is permitted.

   Adequate hepatic function per institutional standards (see exclusion).
8. All patients must be informed of the investigational nature of this study and must sign and give written informed consent.
9. Serum calcium, magnesium and potassium must be within normal limits. Supplementation to achieve normal values is permitted.
10. Patients who are potentially fertile and sexually active must be willing to utilize effective birth control.
11. Patients with CNS metastases which are/were symptomatic must have completed therapy (surgery, gamma knife, XRT) and be neurologically stable.
12. Patients must have \> or = 4 circulating tumor cells

Exclusion Criteria:

1. Patients must not have serious infection or other serious underlying medical condition which would impair the ability of the patient to receive protocol treatment.
2. Current uncontrolled cardiac disease
3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 4 weeks of registration.
5. Patients with acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition or patients known to be HIV positive
6. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Primary outcomes:
measure: Circulating Tumor Cells (CTC)
timeFrame: Day 21
Secondary outcomes:
measure: Myeloid Derived Suppressor Cell (MDSC)
timeFrame: Day 21
Other outcomes:
Locations:
Study officials:
affiliation: University of Maryland Greenebaum Cancer Center
name: Martin Edelman, M.D., FACP
role: PRINCIPAL_INVESTIGATOR
References: